Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decisi...
Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool
About this item
Full title
Author / Creator
Publisher
Santiago: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Santiago: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
In December 2022 the US Food and Drug Administration (FDA) removed the requirement that drugs in development must undergo animal testing before clinical evaluation, a declaration that now demands the establishment and verification of ex vivo preclinical models that closely represent tumor complexity and that can predict therapeutic response. Fortun...
Alternative Titles
Full title
Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_53e2cfa4a35d4a9fae6d1f662c519da0
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_53e2cfa4a35d4a9fae6d1f662c519da0
Other Identifiers
ISSN
0717-6287,0716-9760
E-ISSN
0717-6287
DOI
10.1186/s40659-023-00476-9
